Neurointerventional Balloon Dilatation Catheter Market Report 2026

The neurointerventional balloon dilatation catheter market size has grown rapidly in recent years. It will grow from $1.75 billion in 2025 to $2.06 billion in 2026 at a compound annual growth rate (CAGR) of 17.5%. The growth in the historic period can be attributed to increasing prevalence of cerebrovascular diseases, advancements in catheter design and materials, rising number of neurovascular surgeries, growth of hospital and specialty clinic infrastructure, increasing awareness of minimally invasive procedures.

The neurointerventional balloon dilatation catheter market size is expected to see rapid growth in the next few years. It will grow to $3.96 billion by 2030 at a compound annual growth rate (CAGR) of 17.8%. The growth in the forecast period can be attributed to innovation in compliant and non-compliant balloon technologies, increasing adoption of drug-coated balloons, growth in ambulatory surgical centers, integration with AI-assisted imaging systems, expansion of intracranial treatment applications. Major trends in the forecast period include rising adoption of neurointerventional procedures, increasing use of drug-coated balloon technologies, growing preference for steerable and tapered balloons, expansion of intracranial and extracranial applications, integration of imaging and navigation systems in balloon catheters.

The rising incidence of stroke and intracranial stenosis is anticipated to propel the growth of the neurointerventional balloon dilatation catheter market in the coming years. Stroke is frequently associated with intracranial stenosis, a condition characterized by the narrowing of the brain’s arteries, which elevates the risk of ischemic events. The increasing incidence of stroke and intracranial stenosis is primarily driven by aging populations, as older adults are more vulnerable to arterial constriction and cerebrovascular complications. Neurointerventional balloon dilatation catheters contribute to the treatment of stroke and intracranial stenosis by expanding narrowed brain arteries, restoring optimal blood flow, and mitigating the risk of ischemic occurrences. For example, in December 2025, the Stroke Foundation, an Australia-based non-profit organization, reported that stroke ranks among Australia’s top five causes of mortality, accounting for 9,147 deaths in 2024, with an individual experiencing a stroke every 11 minutes. Therefore, the rising incidence of stroke and intracranial stenosis is expected to support and drive the expansion of the neurointerventional balloon dilatation catheter market.

The growing preference for minimally invasive procedures is also expected to propel the growth of the neurointerventional balloon dilatation catheter market going forward. Minimally invasive procedures are defined as medical or cosmetic interventions conducted with minimal incisions or tissue trauma, often utilizing needles, catheters, or small instruments. This preference is driven by the reduced risk of complications, as such procedures involve smaller incisions and a lower likelihood of infection or bleeding. Neurointerventional balloon dilatation catheters enable minimally invasive treatment by allowing precise expansion of narrowed brain arteries through limited vascular access, thereby minimizing the need for open surgery and reducing recovery time. For instance, in June 2024, the American Society of Plastic Surgeons, a US-based non-profit organization, reported that minimally invasive procedures reached 5.29 million in 2023, reflecting an 8% increase compared to 2022. Therefore, the growing preference for minimally invasive procedures is expected to contribute to the growth of the neurointerventional balloon dilatation catheter market.

The increasing healthcare expenditure is expected to propel the growth of the neurointerventional balloon dilatation catheter market in the forthcoming period. Healthcare expenditure refers to the total financial outlay by a country or organization on health services, medical products, and public health initiatives. The rise in healthcare expenditure is largely driven by the aging population, as older adults require enhanced medical care, ongoing treatments, and long-term health services. Neurointerventional balloon dilatation catheters support the optimization of healthcare expenditure by enabling minimally invasive treatment of intracranial stenosis and stroke, thereby reducing hospital stays, complications, and long-term care costs. For example, in April 2025, the Office for National Statistics, a UK-based government department, reported healthcare expenditure at approximately £317 billion ($399.42 billion), marking a 6.5% nominal increase and a 2.4% real-term rise after adjusting for inflation. Therefore, the increasing healthcare expenditure is expected to support and drive the expansion of the neurointerventional balloon dilatation catheter market.

Major companies operating in the neurointerventional balloon dilatation catheter market are Johnson & Johnson, Medtronic plc, Stryker Corporation, Koninklijke Philips N.V., Boston Scientific Corporation, B. Braun Melsungen AG, Terumo Corporation, Kaneka Corporation, Nipro Corporation, Penumbra Inc., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Asahi Intecc Co. Ltd., APT Medical Inc., Sino Medical Sciences Technology Inc., Peijia Medical Limited, Scientia Vascular Inc., Wallaby Medical Inc., Zylox-Tonbridge Medical Technology Co. Ltd., Acandis GmbH & Co. KG, Princeton Medical Scientific Inc., Cordis a Cardinal Health Company, DK MEDTECH Corporation.

North America was the largest region in the neurointerventional balloon dilatation catheter market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurointerventional balloon dilatation catheter market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurointerventional balloon dilatation catheter market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurointerventional balloon dilatation catheter market consists of sales of angiography contrast media, aspiration catheters, vascular access kits, and hemostatic devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.